{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,2]],"date-time":"2025-08-02T14:35:28Z","timestamp":1754145328943,"version":"3.41.2"},"reference-count":18,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","award":["NCT03737370"],"award-info":[{"award-number":["NCT03737370"]}],"id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007659","name":"Bayer Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.clgc.2025.102368","type":"journal-article","created":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T11:29:19Z","timestamp":1745926159000},"page":"102368","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9155-5903","authenticated-orcid":false,"given":"Brendan","family":"Connell","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0998-323X","authenticated-orcid":false,"given":"Clara","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Edmund","family":"Folefac","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Lawlor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Benjamin","family":"Koethe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4162-8908","authenticated-orcid":false,"given":"Paul","family":"Mathew","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2025.102368_bib0001","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102368_bib0002","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1093\/annonc\/mdw065","article-title":"Patient-reported quality-of-life analysis of radium-223 dichloride from the phase III ALSYMPCA study","volume":"27","author":"Nilsson","year":"2016","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0003","doi-asserted-by":"crossref","first-page":"8232","DOI":"10.1200\/JCO.2005.03.0841","article-title":"Pathogenesis and treatment of prostate cancer bone metastases: targeting the lethal phenotype","volume":"23","author":"Loberg","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0004","doi-asserted-by":"crossref","first-page":"S1254","DOI":"10.1016\/j.annonc.2024.08.2307","volume":"35","author":"Gillessen","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0005","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1001\/jamaoncol.2015.1341","article-title":"Androgen receptor splice variant 7 and efficacy of taxane chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"1","author":"Antonarakis","year":"2015","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0006","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.ejca.2019.04.007","article-title":"Radium-223 in combination with docetaxel in patients with castration-resistant prostate cancer and bone metastases: a phase 1 dose escalation\/randomised phase 2a trial","volume":"114","author":"Morris","year":"2019","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clgc.2025.102368_bib0007","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102368_bib0008","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1200\/JCO.2005.12.187","article-title":"Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone-refractory prostate cancer","volume":"23","author":"Oudard","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0009","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0010","doi-asserted-by":"crossref","first-page":"5021","DOI":"10.1200\/jco.2013.31.15_suppl.5021","article-title":"Safety of radium-223 dichloride (Ra-223) with docetaxel (D) in patients with bone metastases from castration-resistant prostate cancer (CRPC): a phase I prostate cancer clinical trials consortium study","volume":"31","author":"Morris","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0011","doi-asserted-by":"crossref","first-page":"35","DOI":"10.2217\/fon-2021-0886","article-title":"Real-world outcomes of second novel hormonal therapy or radium-223 following first novel hormonal therapy for mCRPC","volume":"18","author":"Sartor","year":"2022","journal-title":"Future Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0012","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102368_bib0013","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2025.102368_bib0014","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1200\/JCO-24-01798","article-title":"Darolutamide in combination with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer from the phase III ARANOTE","volume":"42","author":"Saad","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2025.102368_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20163899","article-title":"The mode-of-action of targeted Alpha Therapy radium-223 as an enabler for novel combinations to treat patients with bone metastasis","volume":"20","author":"Suominen","year":"2019","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clgc.2025.102368_bib0016","doi-asserted-by":"crossref","first-page":"e919","DOI":"10.1016\/j.clgc.2018.03.007","article-title":"Hematologic toxicity from radium-223 therapy for bone metastases in castration-resistant prostate cancer: risk factors and practical considerations","volume":"16","author":"Jacene","year":"2018","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.clgc.2025.102368_bib0017","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2967\/jnumed.122.264456","article-title":"Safety and survival outcomes of (177)Lu-prostate-specific membrane antigen therapy in patients with metastatic castration-resistant prostate cancer with prior (223)Ra treatment: the RALU study","volume":"64","author":"Rahbar","year":"2023","journal-title":"J Nucl Med"},{"key":"10.1016\/j.clgc.2025.102368_bib0018","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1016\/S0140-6736(24)01653-2","article-title":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial","volume":"404","author":"Morris","year":"2024","journal-title":"Lancet"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000692?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767325000692?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T21:13:46Z","timestamp":1752700426000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767325000692"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":18,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1558767325000692"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102368","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dose-Dense Docetaxel and Radium-223 in Bone-Dominant Metastatic Castration-Resistant Prostate Cancer","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2025.102368","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102368"}}